Loading...
•
Dec 31, 2022
C4 Therapeutics Q4 2022 Earnings Report
Reported fourth quarter and full year 2022 financial results.
Key Takeaways
C4 Therapeutics reported its financial results for the year ended December 31, 2022. The company's year-end cash, cash equivalents, and marketable securities are expected to provide runway to the end of 2024.
Progressed the Phase 1/2 Clinical Trial of CFT7455, opening Arm B2 in January 2023 to evaluate CFT7455 in combination with dexamethasone for multiple myeloma treatment.
Shared encouraging initial pharmacokinetic and pharmacodynamic data from the CFT8634 Phase 1/2 clinical trial in January 2023, demonstrating dose-proportional exposure, strong oral bioavailability, and deep BRD9 degradation.
Dosed the first patient in the CFT1946 Phase 1/2 clinical trial in January 2023, with trial sites open and enrolling patients with BRAF V600 mutant cancers.
An Investigational New Drug application for CFT8919 is on track for submission in the first half of 2023.
Forward Guidance
C4T expects that its cash, cash equivalents and marketable securities as of December 31, 2022, together with anticipated collaboration expense reimbursements, but excluding any collaboration option or milestone payments, will enable the company to fund its operating plan to the end of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...